• 中国科技论文统计源期刊
  • 中国科技核心期刊
  • 中国高校优秀期刊
  • 安徽省优秀科技期刊

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

紫杉醇新剂型的研究进展

张倩雯 蒋志文 刘浩

引用本文:
Citation:

紫杉醇新剂型的研究进展

    作者简介: 张倩雯(1989-),女,硕士研究生.
  • 基金项目:

    安徽省高校省级自然科学研究资助项目(KJ2012A202)

    国家自然科学基金资助项目(81000992,81072207)

  • 中图分类号: R944

  • [1] Duan AR,Goodson HV.Taxol-stabilized microtubules promote the formation of filaments from unmodified full-length Tau in vitro[J].Mol Biol Cell,2012,23(24):4796-4806.
    [2] Sudo T,Nitta M,Saya H,et al.Dependence of paclitaxel sensitivity on a functional spindle assembly checkpoin[J].Cancer Res,2004,64(7):2502-2508.
    [3] Wertz IE,Kusam S,Lam C,et al.Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW[J].Nature,2011,471(7336):110-114.
    [4] Blagosklonny MV,Fojo T.Molecular effects of paclitaxel:myths and reality(a critical review)[J].Int J Cancer,1999,83(2):151-156.
    [5] Stearns ME,Wang M.Taxol blocks processes essential for prostate tumor cell(PC-3 ML) invasion and metastases[J].Cancer Res,1992,52(13):3776-3781.
    [6] Adams JD,Flora KP,Goldspiel BR,et al.Taxol:a history of pharmaceutical development and current pharmaceutical concerns[J].J Natl Cancer Inst Monogr,1993(15):141-147.
    [7] Singla AK,Garg A,Aggrawal D.Aggarwal,Paclitaxel and its formulations[J].Int J Pharm,2002,235(1/2):179-192.
    [8] Weiss RB,Donehower RC,Wiernik PH,et al,Hypersensitivity reactions from taxo[J].J Clin Oncol,1990,8(7):1263-1268.
    [9] Kim SC,Yoon HJ,Lee JW,et al.Investigation of the release behavior of DEHP from infusion sets by paclitaxel-loaded polymeric micelles[J].Int J Pharm,2005,293(1/2):303-310.
    [10] Xu Q,Trissel LA,Martinez JF.Stability of paclitaxel in 5% dextrose injection or 0.9% sodium chloride injection at 4,22,or 32 degrees C[J].Am J Hosp Pharm,1994,51(24):3058-3060.
    [11] Erez R,Segal E,Miller K,et al.Enhanced cytotoxicity of a polymer-drug conjugate with triple payload of paclitaxel[J].Bioorg Med Chem,2009,17(13):4327-4335.
    [12] Ye L,He J,Hu Z,et al.Antitumor effect and toxicity of Lipusu in rat ovarian cancer xenografts[J].Food Chem Toxicol,2013,52:200-206.
    [13] Nie S,Hsiao WL,Pan W,et al.Thermoreversible Pluronic F127-based hydrogel containing liposomes for the controlled delivery of paclitaxel:in vitro drug release,cell cytotoxicity,and uptake studies[J].Int J Nanomedicine,2011,6:151-166.
    [14] Bull JL.The application of microbubbles for targeted drug delivery[J].Expert Opin Drug Deliv,2007,4(5):475-493.
    [15] Yan F,Li L,Deng Z,et al.Paclitaxel-liposome-microbubble complexes as ultrasound-triggered therapeutic drug delivery carriers[J].J Control Release,2013,166(3):246-255.
    [16] Wu J,Liu Q,Lee R J.A folate receptor-targeted liposomal formulation for paclitaxel[J].Int J Pharm,2006,316(1/2):148-153.
    [17] Wang X,Deng L,Chen X,et al.Truncated bFGF-mediated cationic liposomal paclitaxel for tumor-targeted drug delivery:improved pharmacokinetics and biodistribution in tumor-bearing mice[J].J Pharm Sci,2011,100(3):1196-1205.
    [18] Yang T,Choi MK,Cui FD,et al.Preparation and evaluation of paclitaxel-loaded PEGylated immunoliposome[J].J Control Release,2007,120(3):169-177.
    [19] Peer D,Margalit R.Tumor-targeted hyaluronan nanoliposomes increase the antitumor activity of liposomal Doxorubicin in syngeneic and human xenograft mouse tumor models[J].Neoplasia,2004,6(4):343-353.
    [20] Penno MB,August JT,Baylin J,et al.Expression of CD44 in human lung tumors[J].Cancer Res,1994,54(5):1381-1387.
    [21] Rivkin I,Cohen K,Koffler J,et al.Paclitaxel-clusters coated with hyaluronan as selective tumor-targeted nanovectors[J].Biomaterials,2010,31(27):7106-7114.
    [22] Yoshizawa Y,Kono Y,Ogawara K,et al.PEG liposomalization of paclitaxel improved its in vivo disposition and anti-tumor efficacy[J].Int J Pharm,2011,412(1/2):132-141.
    [23] Bode C,Trojan L,Weiss C,et al.Paclitaxel encapsulated in cationic liposomes:a new option for neovascular targeting for the treatment of prostate cancer[J].Oncol Rep,2009,22(2):321-326.
    [24] Zhang JQ,Zhang ZR,Yang H,et al.Lyophilized paclitaxel magnetoliposomes as a potential drug delivery system for breast carcinoma via parenteral administration:in vitro and in vivo studies[J].Pharm Res,2005,22(4):573-583.
    [25] Fonseca C,Simoes S,Gaspar R.Paclitaxel-loaded PLGA nanoparticles:preparation,physicochemical characterization and in vitro anti-tumoral activity[J].J Control Release,2002,83(2):273-286.
    [26] Monsky WL,Fukumura D,Gohongi T,et al.Augmentation of transvascular transport of macromolecules and nanoparticles in tumors using vascular endothelial growth factor[J].Cancer Res,1999,59(16):4129-4135.
    [27] Paal K,Muller J,Hegedus L.High affinity binding of paclitaxel to human serum albumin[J].Eur J Biochem,2001,268(7):2187-2191.
    [28] Desai N,Trieu V,Yao Z,et al.Increased antitumor activity,intratumor paclitaxel concentrations,and endothelial cell transport of cremophor-free,albumin-bound paclitaxel,ABI-007,compared with cremophor-based paclitaxel[J].Clin Cancer Res,2006,12(4):1317-1324.
    [29] Wang G,Yu B,Wu Y,et al.Controlled preparation and antitumor efficacy of vitamin E TPGS -functionalized PLGA nanoparticles for delivery of paclitaxe[J].l.Int J Pharm,2013,446(1/2):24-33.
    [30] Smitha KT,Anitha A,Furuike T,et al.In vitro evaluation of paclitaxel loaded amorphous chitin nanoparticles for colon cancer drug delivery[J].Colloids Surf B Biointerfaces,2012,104:245-253.
    [31] Xia H,Gu GZ,Hu QY,et al.Activatable cell penetrating peptide-conjugated nanoparticles with enhanced permeability for site-specific targeting delivery of anticancer drug[J].Bioconjug Chem,2013,24(3):419-430.
    [32] Jia L,Shen J,Li Z,et al.In vitro and in vivo evaluation of paclitaxel-loaded mesoporous silica nanoparticles with three pore sizes[J].Int J Pharm,2013,445(1/2):12-19.
    [33] Wang F,Zhang D,Zhang Q,et al.Synergistic effect of folate-mediated targeting and verapamil-mediated P-gp inhibition with paclitaxel -polymer micelles to overcome multi-drug resistance[J].Biomaterials,2011,32(35):9444-9456.
    [34] Gong C,Xie Y,Wu Q,et al.Improving anti-tumor activity with polymeric micelles entrapping paclitaxel in pulmonary carcinoma[J].Nanoscale,2012,4(19):6004-6017.
    [35] Tao Y,Han J,Wang X,et al.Nano-formulation of paclitaxel by vitamin E succinate functionalized pluronic micelles for enhanced encapsulation,stability and cytotoxicity[J].Colloids Surf B Biointerfaces,2013,102:604-610.
    [36] Nuijen B,Bouma M,Schellens JH,et al.Progress in the development of alternative pharmaceutical formulations of taxanes[J].Invest New Drugs,2001,19(2):143-153.
    [37] Mellado W,Magri NF,Kingston DG,et al.Preparation and biological activity of taxol acetates[J].Biochem Biophys Res Commun,1984,124(2):329-336.
    [38] Vyas DM,Wong H,Crosswell AR,et al.Synthesis and antitumor evaluation of water soluble taxol phosphates[J].Bioorganic and Med Chem Lett,1993,36(13):1797-1801.
    [39] Homsi J,Bedikian AY,Kim KB,et al.Phase 2 open-label study of weekly docosahexaenoic acid-paclitaxel in cutaneous and mucosal metastatic melanoma patients[J].Melanoma Res,2009,19(4):238-242.
    [40] Elsadek B,Graeser R,Esser N,et al.Development of a novel prodrug of paclitaxel that is cleaved by prostate-specific antigen:an in vitro and in vivo evaluation study[J].Eur J Cancer,2010,46(18):3434-3444.
    [41] Terwogt JM,Nuijen B,Huinink WW,et al.Alternative formulations of paclitaxel[J].Cancer Treat Rev,1997,23(2):87-95.
    [42] Heldman AW,Cheng L,Jenkins GM,et al.Paclitaxel stent coating inhibits neointimal hyperplasia at 4 weeks in a porcine model of coronary restenosis[J].Circulation,2001,103(18):2289-2295.
    [43] Dake MD,Van Alstine WG,Zhou Q,et al.Polymer-free paclitaxel-coated Zilver PTX Stents--evaluation of pharmacokinetics and comparative safety in porcine arteries[J].J Vasc Interv Radiol,2011,22(5):603-610.
  • [1] 许河南王月月陈天天闫雷王文锐杨清玲陈昌杰 . 紫杉醇长循环纳米胶束的制备及其对乳腺癌多药耐药的研究. 蚌埠医学院学报, 2019, 44(9): 1142-1147. doi: 10.13898/j.cnki.issn.1000-2200.2019.09.002
    [2] 董正远许河南王文锐杨清玲陈昌杰 . 紫杉醇长循环纳米胶束联合vMIP-ⅡN端肽逆转乳腺癌细胞耐药的研究. 蚌埠医学院学报, 2020, 45(9): 1141-1146. doi: 10.13898/j.cnki.issn.1000-2200.2020.09.001
    [3] 李维辰袁易 . 2007~2009年我院处方药物使用调查及分析. 蚌埠医学院学报, 2010, 35(6): 612-614.
    [4] 王洪亚韩啸王子安 . 紫杉醇联合顺铂治疗中晚期非小细胞肺癌34例分析. 蚌埠医学院学报, 2009, 34(8): 682-684.
    [5] 吴子琳魏少美彭可勤沈学敏 . 紫杉醇联合表阿霉素治疗乳腺癌不良反应的护理. 蚌埠医学院学报, 2010, 35(1): 94-96.
    [6] 鲍时杰夏国安王文舟 . 紫杉醇联合表阿霉素治疗晚期乳腺癌临床观察. 蚌埠医学院学报, 2009, 34(8): 704-705.
    [7] 马珊珊马玲 . 姜黄素逆转卵巢癌对紫杉醇耐药的实验研究. 蚌埠医学院学报, 2016, 41(10): 1269-1272. doi: 10.13898/j.cnki.issn.1000-2200.2016.10.003
    [8] 王荣俊童斯浩 . 姜黄素联合紫杉醇对肺癌细胞PC9凋亡的影响. 蚌埠医学院学报, 2016, 41(12): 1549-1551. doi: 10.13898/j.cnki.issn.1000-2200.2016.12.003
    [9] 崔秀娟 . 白藜芦醇与紫杉醇联合应用对肺癌细胞PC9的杀伤效应. 蚌埠医学院学报, 2015, 40(8): 994-997,1001. doi: 10.13898/j.cnki.issn.1000-2200.2015.08.003
    [10] 王亮亮李玉芝王丽华 . 紫杉醇联合奈达铂术前辅助治疗局部晚期宫颈癌30例. 蚌埠医学院学报, 2015, 40(10): 1330-1332.
    [11] 周俭胡文军孙翠玲 . 紫杉醇联合亚叶酸钙和5-氟尿嘧啶治疗晚期胃癌临床观察. 蚌埠医学院学报, 2012, 36(7): 806-807.
    [12] 汪志求韩光锋段爱雄 . 紫杉醇联合顺铂方案同步放化疗治疗中晚期宫颈癌近期疗效观察. 蚌埠医学院学报, 2012, 36(9): 1048-1050.
    [13] 赵伟庆季枚吴昌平 . 国产紫杉醇联合顺铂治疗晚期非小细胞肺癌40例疗效观察. 蚌埠医学院学报, 2006, 31(2): 146-148.
    [14] 潘明郑中显徐金发刘飞宋文灿 . 紫杉醇联合顺铂、氟尿嘧啶治疗晚期上消化道癌43例临床分析. 蚌埠医学院学报, 2007, 32(4): 451-452.
    [15] 王有猛阚庆生 . 紫杉醇联合奥沙利铂治疗非小细胞肺癌疗效分析. 蚌埠医学院学报, 2010, 35(10): 1023-1024.
    [16] 孙翠玲田添高莹莹胡文军 . 紫杉醇联合卡培他滨或氟尿嘧啶一线治疗晚期胃癌临床对照研究. 蚌埠医学院学报, 2016, 41(2): 194-196. doi: 10.13898/j.cnki.issn.1000-2200.2016.02.018
    [17] 王蓓蓓李玉芝王丽华李燕华郭祥瑞 . 紫杉醇或多西他赛联合奈达铂在宫颈癌新辅助化疗中的疗效及安全性. 蚌埠医学院学报, 2017, 42(7): 864-867. doi: 10.13898/j.cnki.issn.1000-2200.2017.07.008
    [18] 高峰 . 食管癌研究现状综述. 蚌埠医学院学报, 2010, 35(6): 645-648.
    [19] 闵曦夏荣 . 紫外线催化用于口腔种植体二氧化钛纳米管表面活化的研究进展. 蚌埠医学院学报, 2015, 40(6): 840-841. doi: 10.13898/j.cnki.issn.1000-2200.2015.06.048
    [20] 靳丽杰方美丽叶国柳 . 局部晚期宫颈癌新辅助化疗25例近期疗效观察. 蚌埠医学院学报, 2012, 36(8): 910-912.
  • 加载中
计量
  • 文章访问数:  2395
  • HTML全文浏览量:  192
  • PDF下载量:  326
  • 被引次数: 0
出版历程
  • 收稿日期:  2013-02-28

紫杉醇新剂型的研究进展

    作者简介: 张倩雯(1989-),女,硕士研究生.
  • 蚌埠医学院 药学系, 安徽省生化药物工程技术研究中心, 安徽 蚌埠 233030
基金项目:  安徽省高校省级自然科学研究资助项目(KJ2012A202)国家自然科学基金资助项目(81000992,81072207)
参考文献 (43)

目录

    /

    返回文章
    返回